JP2003531578A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003531578A5 JP2003531578A5 JP2001561063A JP2001561063A JP2003531578A5 JP 2003531578 A5 JP2003531578 A5 JP 2003531578A5 JP 2001561063 A JP2001561063 A JP 2001561063A JP 2001561063 A JP2001561063 A JP 2001561063A JP 2003531578 A5 JP2003531578 A5 JP 2003531578A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- cells
- cell
- immunization
- vitro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000003719 b-lymphocyte Anatomy 0.000 description 15
- 239000000427 antigen Substances 0.000 description 14
- 102000036639 antigens Human genes 0.000 description 13
- 108091007433 antigens Proteins 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 10
- 230000003053 immunization Effects 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 6
- 230000004913 activation Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 3
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 230000003844 B-cell-activation Effects 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 108010033737 Pokeweed Mitogens Proteins 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 210000004116 schwann cell Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/491,894 | 2000-01-26 | ||
| US09/491,894 US6541225B1 (en) | 2000-01-26 | 2000-01-26 | Methods and compositions for generating human monoclonal antibodies |
| PCT/US2001/002588 WO2001055216A1 (en) | 2000-01-26 | 2001-01-26 | Methods and compositions for generating human monoclonal antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003531578A JP2003531578A (ja) | 2003-10-28 |
| JP2003531578A5 true JP2003531578A5 (cg-RX-API-DMAC10.html) | 2011-06-30 |
| JP4790959B2 JP4790959B2 (ja) | 2011-10-12 |
Family
ID=23954109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001561063A Expired - Fee Related JP4790959B2 (ja) | 2000-01-26 | 2001-01-26 | ヒトモノクローナル抗体を産生するための方法および組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US6541225B1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP1255780B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP4790959B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR20020073185A (cg-RX-API-DMAC10.html) |
| CN (1) | CN100491397C (cg-RX-API-DMAC10.html) |
| AT (1) | ATE439380T1 (cg-RX-API-DMAC10.html) |
| AU (2) | AU2001231172B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2398284A1 (cg-RX-API-DMAC10.html) |
| DE (1) | DE60139542D1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2001055216A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6541225B1 (en) * | 2000-01-26 | 2003-04-01 | Raven Biotechnologies, Inc. | Methods and compositions for generating human monoclonal antibodies |
| US6794141B2 (en) * | 2000-12-22 | 2004-09-21 | Arcturus Bioscience, Inc. | Nucleic acid amplification |
| US20030096414A1 (en) * | 2001-03-27 | 2003-05-22 | Invitrogen Corporation | Culture medium for cell growth and transfection |
| GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
| JP2007514752A (ja) * | 2003-12-16 | 2007-06-07 | ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス | Ｇｌｐ−１医薬組成物 |
| US7771999B2 (en) * | 2004-04-28 | 2010-08-10 | Vaxdesign Corp. | Disease model incorporation into an artificial immune system (AIS) |
| US8071373B2 (en) | 2004-04-28 | 2011-12-06 | Sanofi Pasteur Vaxdesign Corp. | Co-culture lymphoid tissue equivalent (LTE) for an artificial immune system (AIS) |
| US7855074B2 (en) | 2004-04-28 | 2010-12-21 | Vaxdesign Corp. | Artificial immune system: methods for making and use |
| US7709256B2 (en) * | 2004-04-28 | 2010-05-04 | Vaxdesign Corp. | Disease model incorporation into an artificial immune system (AIS) |
| US8030070B2 (en) * | 2004-04-28 | 2011-10-04 | Sanofi Pasteur Vaxdesign Corp. | Artificial lymphoid tissue equivalent |
| US7785883B2 (en) * | 2004-04-28 | 2010-08-31 | Vax Design Corp. | Automatable artificial immune system (AIS) |
| US8298824B2 (en) | 2004-04-28 | 2012-10-30 | Sanofi Pasteur Vaxdesign Corporation | Methods of evaluating a test agent in a diseased cell model |
| US7785806B2 (en) * | 2004-04-28 | 2010-08-31 | Vaxdesign Corporation | Method for determining the immunogenicity of an antigen |
| KR101295139B1 (ko) * | 2004-06-07 | 2013-08-12 | 레이븐 바이오테크놀로지스, 인코퍼레이티드 | 트랜스페린 리셉터 항체 |
| WO2006084078A2 (en) * | 2005-02-02 | 2006-08-10 | Raven Biotechnologies, Inc. | Jam-3 and antibodies that bind thereto |
| CA2597171A1 (en) * | 2005-02-03 | 2006-08-10 | Raven Biotechnologies, Inc. | Antibodies to oncostatin m receptor |
| BRPI0607450A2 (pt) * | 2005-02-04 | 2009-09-01 | Raven Biotechnologies Inc | anticorpos que se ligam a epha2 e métodos para sua utilização |
| EP2343363A1 (en) * | 2005-07-01 | 2011-07-13 | John Schrader | Methods of isolating cells and generating monoclonal antibodies involving single epitope multiple staining |
| JP2009521228A (ja) * | 2005-12-21 | 2009-06-04 | ヴァックスデザイン コーポレーション | 単球の樹状細胞への分化を促進する多孔質膜デバイス |
| CA2634123C (en) * | 2005-12-21 | 2015-11-24 | Vaxdesign Corporation | In vitro germinal centers |
| KR100850416B1 (ko) * | 2006-06-21 | 2008-08-04 | 남상윤 | 자가세포 파괴에 의해 야기되는 자가면역질환의 치료를위한 세포치료제 및 그 제조 방법 |
| US7709257B2 (en) * | 2006-06-27 | 2010-05-04 | Vax Design Corp. | Models for vaccine assessment |
| RU2448979C2 (ru) * | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
| US20090104221A1 (en) * | 2007-07-06 | 2009-04-23 | Vaxdesign Corporation | Rapid generation of t cell-independent antibody responses to t cell-dependent antigens |
| WO2009048661A1 (en) | 2007-07-16 | 2009-04-16 | Vaxdesign Corporation | Artificial tissue constructs comprising alveolar cells and methods for using the same |
| WO2009020923A1 (en) | 2007-08-03 | 2009-02-12 | Musc Foundation For Research Development | Human monoclonal antibodies and methods for producing the same |
| WO2009054556A1 (en) * | 2007-10-24 | 2009-04-30 | Sang Yun Nam | Method for preparation of therapeutic b cells against autoimmune diseases which are induced by autoimmune cytotoxicity |
| WO2009072660A1 (ja) * | 2007-12-03 | 2009-06-11 | Kabushiki Kaisya Advance | 抗体作製方法 |
| WO2009105150A2 (en) * | 2008-01-28 | 2009-08-27 | Thomas Jefferson University | Method of making hybrid cells that express useful antibodies |
| CN106349390B (zh) | 2008-04-02 | 2019-12-10 | 宏观基因有限公司 | Bcr-复合体-特异性抗体和其使用方法 |
| PH12012501751A1 (en) | 2010-03-04 | 2012-11-12 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| DK2542256T3 (da) | 2010-03-04 | 2019-08-26 | Macrogenics Inc | Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf |
| SI2400298T1 (sl) * | 2010-05-28 | 2013-11-29 | F. Hoffmann-La Roche Ag | Postopek kultivacije posamezne B-celice in izdelava specifičnih protiteles |
| TWI477603B (zh) * | 2011-01-28 | 2015-03-21 | 鴻海精密工業股份有限公司 | 培育基體之製備方法 |
| EP3363813A1 (en) | 2011-06-23 | 2018-08-22 | Ablynx NV | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains |
| CA3141978A1 (en) | 2011-06-23 | 2012-12-27 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| EP2724157B1 (en) * | 2011-06-27 | 2017-03-08 | Valneva | Method for screening cells |
| CN102321720B (zh) * | 2011-07-28 | 2014-09-03 | 万晓春 | 一种混合细胞培养生产纯人源单克隆抗体的方法 |
| EP2727942A1 (en) | 2012-11-05 | 2014-05-07 | MAB Discovery GmbH | Bispecific antibodies against human EGFR, HER2, and HER3 |
| WO2014067642A1 (en) | 2012-11-05 | 2014-05-08 | Mab Discovery Gmbh | Method for the production of multispecific antibodies |
| EP2727941A1 (en) | 2012-11-05 | 2014-05-07 | MAB Discovery GmbH | Method for the production of multispecific antibodies |
| EP2727943A1 (en) | 2012-11-05 | 2014-05-07 | MAB Discovery GmbH | Trispecific antibodies against human EGFR, HER2 and HER3 |
| US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
| CN108026172B (zh) | 2015-06-26 | 2022-04-29 | 赛诺菲生物技术公司 | 单克隆抗il-1racp抗体 |
| US9395367B1 (en) | 2016-02-29 | 2016-07-19 | Rarecyte, Inc. | Method to identify antigen-specific B cells for antibody development |
| US9442113B1 (en) | 2016-02-29 | 2016-09-13 | Rarecyte, Inc. | Method to identify antigen-specific immune cells for therapeutic development |
| US10222373B2 (en) | 2016-02-29 | 2019-03-05 | Rarecyte, Inc. | Method to identify antigen-specific immune cells |
| CN109069633A (zh) | 2016-04-15 | 2018-12-21 | 宏观基因有限公司 | 新颖的b7-h3-结合分子、其抗体药物缀合物及其使用方法 |
| EP3241845A1 (en) | 2016-05-06 | 2017-11-08 | MAB Discovery GmbH | Humanized anti-il-1r3 antibodies |
| EP3401332A1 (en) | 2017-05-08 | 2018-11-14 | MAB Discovery GmbH | Anti-il-1r3 antibodies for use in inflammatory conditions |
| TW202016144A (zh) * | 2018-06-21 | 2020-05-01 | 日商第一三共股份有限公司 | 包括cd3抗原結合片段之組成物及其用途 |
| US12054552B2 (en) | 2022-09-21 | 2024-08-06 | Sanofi Biotechnology | Humanized anti-IL-1R3 antibody and methods of use |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4643971A (en) * | 1983-03-11 | 1987-02-17 | Sloan-Kettering Institute | Monoclonal antibodies to human bladder and ureter cancers and method |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| EP0218158A3 (en) | 1985-09-30 | 1988-12-07 | Asahi Kasei Kogyo Kabushiki Kaisha | Human monoclonal antibody, B-cell line for producing this antibody and method for preparing this B-cell line and antibody. |
| US6150584A (en) * | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| DE69126281T2 (de) * | 1990-11-26 | 1997-10-16 | Akzo Nobel Nv | Verfahren zur Herstellung von Antikörpern |
| US5256542A (en) * | 1992-03-09 | 1993-10-26 | Tanox Biosystems, Inc. | Selecting low frequency antigen-specific single B lymphocytes with correction for background noise |
| US5747034A (en) * | 1992-07-09 | 1998-05-05 | Chiron Corporation | Methods and materials for the induction of T cell anergy |
| JPH09503901A (ja) | 1992-11-16 | 1997-04-22 | キャンサー リサーチ ファンド オブ コントラ コスタ | 広範な新生物特異性を有するペプチドおよびアンチセンスペプチド |
| GB9526131D0 (en) * | 1995-12-21 | 1996-02-21 | Celltech Therapeutics Ltd | Recombinant chimeric receptors |
| US5882644A (en) * | 1996-03-22 | 1999-03-16 | Protein Design Labs, Inc. | Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof |
| IL122233A (en) * | 1996-12-06 | 2001-04-30 | Akzo Nobel Nv | Method of generating monoclonal antibodies to cell wall and pharmaceutical preparations and diagnostic agents containing them |
| EP0983303B1 (en) * | 1997-05-21 | 2006-03-08 | Biovation Limited | Method for the production of non-immunogenic proteins |
| US6004528A (en) * | 1997-09-18 | 1999-12-21 | Bergstein; Ivan | Methods of cancer diagnosis and therapy targeted against the cancer stemline |
| US6541225B1 (en) * | 2000-01-26 | 2003-04-01 | Raven Biotechnologies, Inc. | Methods and compositions for generating human monoclonal antibodies |
-
2000
- 2000-01-26 US US09/491,894 patent/US6541225B1/en not_active Expired - Lifetime
-
2001
- 2001-01-26 WO PCT/US2001/002588 patent/WO2001055216A1/en not_active Ceased
- 2001-01-26 AU AU2001231172A patent/AU2001231172B2/en not_active Ceased
- 2001-01-26 DE DE60139542T patent/DE60139542D1/de not_active Expired - Lifetime
- 2001-01-26 KR KR1020027009598A patent/KR20020073185A/ko not_active Ceased
- 2001-01-26 AU AU3117201A patent/AU3117201A/xx active Pending
- 2001-01-26 CN CNB018056997A patent/CN100491397C/zh not_active Expired - Fee Related
- 2001-01-26 EP EP01903344A patent/EP1255780B1/en not_active Expired - Lifetime
- 2001-01-26 AT AT01903344T patent/ATE439380T1/de not_active IP Right Cessation
- 2001-01-26 CA CA002398284A patent/CA2398284A1/en not_active Abandoned
- 2001-01-26 JP JP2001561063A patent/JP4790959B2/ja not_active Expired - Fee Related
-
2002
- 2002-12-20 US US10/327,423 patent/US20030109006A1/en not_active Abandoned
-
2006
- 2006-07-06 US US11/482,660 patent/US8137668B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Seder et al. | CD8+ T cells can be primed in vitro to produce IL-4 | |
| Wigzell et al. | Separation of Normal and Immune Lymphoid Cells by Antigen-Coated Columns: Antigen-Binding Characteristics of Membrane Antibodies as Analyzed by Hapten-Protein Antigens | |
| US4464465A (en) | Cell-driven viral transfer in eukaryotes | |
| Kupfer et al. | Polarized expression of cytokines in cell conjugates of helper T cells and splenic B cells. | |
| Mond et al. | Role of T lymphocytes in the response to TNP-AECM-Ficoll. | |
| Taniguchi et al. | Antigen-specific suppressive factor produced by a transplantable IJ bearing T-cell hybridoma | |
| Plebanski et al. | Primary and secondary human in vitro T-cell responses to soluble antigens are mediated by subsets bearing different CD45 isoforms | |
| JP2021509586A5 (cg-RX-API-DMAC10.html) | ||
| Snow et al. | Activation of antigen-enriched b cells. I. Purification and response to thymus-independent antigens. | |
| JP2009148266A (ja) | 未分化細胞の製造方法 | |
| Hoppenbrouwers et al. | Specific polyunsaturated fatty acids can modulate in vitro human moDC2s and subsequent Th2 cytokine release | |
| JP2002536023A5 (cg-RX-API-DMAC10.html) | ||
| Birdwell et al. | Replication of Sindbis Virus IV. Electron Microscope Study of the Insertion of Viral Glycoproteins into the Surface of Infected Chick Cells | |
| Lee et al. | Limiting dilution analysis of CD45Rhi and CD45Rlo T cells: further evidence that CD45Rlo cells are memory cells | |
| Xiao et al. | Mechanisms of recovery from experimental allergic encephalomyelitis induced with myelin basic protein peptide 68–86 in Lewis rats: a role for dendritic cells in inducing apoptosis of CD4+ T cells | |
| Schrader et al. | Dendritic cell dependent expression of IgA by clones in T/B microcultures | |
| Plebanski et al. | In vitro primary responses of human T cells to soluble protein antigens | |
| US4228236A (en) | Process of producing carcinoembryonic antigen | |
| EP0057107A3 (en) | Method of manufacturing monoclonal antibodies and cells capable of manufacturing such antibodies | |
| Sanders et al. | Interleukin 4 enhances the ability of antigen-specific B cells to form conjugates with T cells. | |
| ATE120796T1 (de) | Trennungsverfahren zum trennen von hämatopoeitischen vorläuferzellen. | |
| Ozaki et al. | Production of TT hybrids from T cell clones. Direct comparison between cloned T cells and T hybridoma cells derived from them. | |
| Borrebaeck | Development of in vitro immunization in murine and human hybridoma technology | |
| Savonnière et al. | Effects of lipid supplementation of culture media on cell growth, antibody production, membrane structure and dynamics in two hybridomas | |
| Xin et al. | In vitro maturation and migration of immature dendritic cells after chemokine receptor 7 transfection |